Tag Archives: ILDs

Ofev Approved for Chronic Fibrosing ILDs With Progressive Phenotype

TUESDAY, March 10, 2020 — Ofev (nintedanib) oral capsules have received the first approval for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, the U.S. Food and Drug Administration announced Monday. Ofev, a multitargeted tyrosine kinase inhibitor, was approved in 2014 to treat idiopathic pulmonary fibrosis and to… Read More »